What is VRDN's current stock price?

VRDN (Viridian Therapeutics, Inc.) is currently trading at $17.24 with a market cap of $1.55B.

What sector is Viridian Therapeutics, Inc. in?

Viridian Therapeutics, Inc. (VRDN) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is VRDN a good stock to buy?

Analysts have a Buy consensus on VRDN with a price target of $38.13. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

VRDN Viridian Therapeutics, Inc.

Healthcare

$17.24-2.54%ClosedMarket Cap: $1.55B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.77

P/S

21.88

EV/EBITDA

-3.92

DCF Value

$-8.17

FCF Yield

-19.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

99.4%

Operating Margin

-543.9%

Net Margin

-508.5%

ROE

-60.7%

ROA

-45.7%

ROIC

-52.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$141.0K	$-104.9M	$—
Q4 null	$132.0K	$-120.4M	$—
FY null	$70.8M	$-342.6M	$—
Q3 null	$70.6M	$-34.6M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$38.13

Target (Median)

$36.50

Target Range

$26.00 - $50.00

3 Strong Buy13 Buy1 Hold0 Sell0 Strong Sell

Evercore ISI GroupOutperform

2026-05-15

RBC CapitalOutperform

2026-05-06

NeedhamBuy

2026-05-05

Truist SecuritiesBuy

2026-04-21

WedbushOutperform

2026-04-08

Trading Activity

Insider Trades

View All

Fairmount Funds Management LLCdirector, 10 percent owner:

BuyWed May 13

Tousignant Jenniferofficer: Chief Legal Officer

SellMon Mar 09

Mahoney Stephen F.director, officer: President and CEO

SellMon Mar 09

Harmon Sethofficer: Chief Financial Officer

SellMon Mar 09

Beetham Thomas W.officer: Chief Operating Officer

SellMon Mar 09

Latest News

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease TranscriptSeeking Alpha · Tue May 05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.82

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Peers